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ABSTRACT Non-Staphylococcus aureus staphylococcal species (non-SASS) are important
pathogens in both animal and human populations. The development of ␤-lactam resistance in non-SASS through acquisition and expression of penicillin-binding protein 2a
(PBP2a) represents a signiﬁcant clinical and public health threat. Here, we evaluated
the diagnostic performance of two versions of a PBP2a immunochromatographic assay with non-SASS. Our data show that the revised version of the assay, the PBP2a
SA culture colony test, has superior diagnostic sensitivity compared to the previous
version of the assay, the PBP2a culture colony test, 100% (95% conﬁdence interval
[CI], 93.3 to 100%) versus 67.9% (95% CI, 53.7 to 80.1%), respectively, while both assays display a speciﬁcity of 100% (95% CI, 92.5 to 100%). Therefore, the PBP2a SA
culture colony test offers a rapid, accurate, and relatively inexpensive method for detecting PBP2a-mediated ␤-lactam resistance in clinically relevant non-SASS for the
management of infections due to these organisms and for antimicrobial stewardship.
KEYWORDS beta-lactam resistance, methicillin resistance, PBP2a, Staphylococcus

S

taphylococcus aureus is the primary pathogenic Staphylococcus species in human
populations; however, other staphylococcal species can cause serious disease in
both humans and animals (1). Several non-S. aureus staphylococcal species (non-SASS),
e.g., Staphylococcus epidermidis and Staphylococcus haemolyticus, are notable nosocomial pathogens (1). In addition, Staphylococcus lugdunensis causes infectious endocarditis and skin and soft tissue infections (2, 3), while other species, especially members
of the Staphylococcus intermedius group (notably Staphylococcus pseudintermedius), are
signiﬁcant animal pathogens (4).
Treatment of infections due to these and other non-SASS is impeded by their ability
to acquire resistance to important therapeutic agents, including ␤-lactams (1). In
staphylococci, resistance to ␤-lactams is predominantly conferred by the acquisition of
an alternative transpeptidase, penicillin-binding protein 2a (PBP2a or PBP2=), which is
encoded by the mecA gene and catalyzes the synthesis of the bacterial cell wall
(peptidoglycan) in otherwise inhibitory concentrations of ␤-lactams (1, 5). Isolates that
harbor PBP2a are resistant to all ␤-lactams, with the exception of ceftobiprole and
ceftaroline (1, 5), and pose a signiﬁcant clinical and public health threat.
Therefore, accurate, rapid, and inexpensive methods to detect PBP2a in staphyloApril 2019 Volume 57 Issue 4 e01417-18

Journal of Clinical Microbiology

Citation Canver MC, Gonzalez MD, Ford BA,
Arnold AR, Lawhon SD, Burnham C-AD, Jenkins
SG, Burd EM, Westblade LF. 2019. Improved
performance of a rapid immunochromatographic
assay for detection of PBP2a in non-Staphylococcus
aureus staphylococcal species. J Clin Microbiol 57:
e01417-18. https://doi.org/10.1128/JCM.01417-18.
Editor Karen C. Carroll, Johns Hopkins
University School of Medicine
Copyright © 2019 American Society for
Microbiology. All Rights Reserved.
Address correspondence to Lars F. Westblade,
law9067@med.cornell.edu.
* Present address: Amanda R. Arnold,
Neuroscience Institute, Georgia State
University, Atlanta, Georgia, USA.
M.C.C. and M.D.G. contributed equally to this
work.
Received 2 September 2018
Returned for modiﬁcation 24 September
2018
Accepted 15 January 2019
Accepted manuscript posted online 16
January 2019
Published 28 March 2019

jcm.asm.org 1

Downloaded from http://jcm.asm.org/ on April 26, 2019 by guest

Matthew C. Canver,a Mark D. Gonzalez,b Bradley A. Ford,c Amanda R. Arnold,b* Sara D. Lawhon,d
Carey-Ann D. Burnham,e Stephen G. Jenkins,a Eileen M. Burd,f Lars F. Westbladea

Canver et al.

Journal of Clinical Microbiology

Downloaded from http://jcm.asm.org/ on April 26, 2019 by guest

cocci can greatly facilitate management of infections due to these organisms, as well as
antimicrobial stewardship efforts (6). Nucleic acid-based mecA detection methods are
rapid and accurate but can be expensive and require dedicated instrumentation that
prohibits their widespread adoption, especially in resource-limited settings. In contrast,
rapid immunologic detection of PBP2a is relatively inexpensive, does not require
specialized instrumentation, and is simple to perform in almost any laboratory setting.
The PBP2a culture colony test (Alere, Scarborough, ME), which was discontinued,
was an immunochromatographic assay that employed monoclonal antibodies to detect
PBP2a in S. aureus isolated in culture (7). The assay exhibited a sensitivity between 94.1
and 100% and a speciﬁcity between 98.8 and 100% for detection of PBP2a in S. aureus
(6–8). In contrast, this assay demonstrated sensitivity and speciﬁcity with non-SASS of
86% and 100%, respectively (8), with the notable exceptions of S. lugdunensis, Staphylococcus schleiferi, and members of the S. intermedius group, where sensitivity and
speciﬁcity were 100% (9).
In 2015, a revised version of the assay was released in the United States, the PBP2a
SA culture colony test (Alere, Scarborough, ME), which utilizes recombinant monoclonal
antibody fragments to detect PBP2a in S. aureus isolated in culture. The sensitivity and
speciﬁcity of the assay for S. aureus are reported to be ⬎98% (10). In addition, a study
examining atypical S. aureus isolates demonstrated a sensitivity of ⱖ90% and a speciﬁcity of 100% (11). However, limited data are available for non-SASS isolates, with the
exception of recent work evaluating 54 S. schleiferi isolates, where the PBP2a SA culture
colony test had a sensitivity and speciﬁcity of 100% (12). Therefore, we sought to
determine the performance of the PBP2a SA culture colony test using a collection of
100 non-SASS isolates composed of 10 species obtained from animal and human
subjects collected from four geographically distinct regions in the United States:
Georgia (two distinct sites), Iowa, Missouri, and Texas.
MATERIALS AND METHODS
Bacterial isolates. Bacterial isolates were identiﬁed to the species level using matrix-assisted laser
desorption ionization–time of ﬂight mass spectrometry (Bruker Daltonics, Inc., Billerica, MA) (13). One
hundred clinical isolates were chosen based on isolate availability and included species commonly
recovered from human clinical specimens (1). While the majority of isolates were coagulase-negative
species, S. pseudintermedius and S. schleiferi have coagulase activity and were also included in this study
because they represent important animal- and human-associated pathogens (4, 14, 15). The non-SASS
clinical isolates were recovered from adult and pediatric populations (with the exception of two S.
pseudintermedius and two S. schleiferi isolates obtained from animals) across four geographically distinct
regions of the United States and included ﬁve separate centers, as follows: site 1, Children’s Healthcare
of Atlanta (Atlanta, GA; n ⫽ 35); site 2, Emory University School of Medicine (Atlanta, GA; n ⫽ 26); site 3,
University of Iowa Carver College of Medicine (Iowa City, IA; n ⫽ 16); site 4, Texas A&M College of
Veterinary Medicine (College Station, TX; n ⫽ 4), and site 5, Washington University in St. Louis School of
Medicine (St. Louis, MO; n ⫽ 19).
Multiplex mecA PCR. The mecA PCR was performed as previously described (9) by multiple operators
at one location (Children’s Healthcare of Atlanta). Brieﬂy, a multiplex PCR was used to detect the mecA
gene, together with an internal control (a portion of the 16S rRNA gene). Bacterial extracts were
resuspended in 50 l of nuclease-free water and incubated at 100°C for 10 min. After removal of cellular
debris by centrifugation, PCRs were set up with a ﬁnal reaction volume of 20 l, consisting of 2 l
bacterial extracts (⬃50 to 200 ng DNA), 0.5 M primers, and 1⫻ AmpliTaq Gold Fast PCR master mix
(Applied Biosystems, Foster City, CA). Samples were subjected to the following cycling conditions: 95°C
for 10 min; 35 cycles of 96°C for 3 s, 52°C for 3 s, and 68°C for 5 s; and 72°C for 10 sec. Agarose gel
electrophoresis was used to visualize the PCR products. On each day of testing, positive (S. aureus ATCC
43300) and negative (S. aureus ATCC 25923) controls were performed.
Cefoxitin and oxacillin disk diffusion. Cefoxitin disk (30 g; Becton, Dickinson and Company [BD],
Franklin Lakes, NJ) diffusion was performed for all Staphylococcus species (except S. pseudintermedius and
S. schleiferi) at one location (Children’s Healthcare of Atlanta) by a single operator, while oxacillin disk
(1 g; BD) diffusion was performed for S. pseudintermedius and S. schleiferi at another site (NewYorkPresbyterian Hospital–Weill Cornell Medical Center, New York, NY) by a single operator, and the results
were interpreted according to the Clinical and Laboratory Standards Institute (CLSI) recommendations
(16).
Immunochromatographic detection of PBP2a. The PBP2a culture colony test permits detection of
PBP2a in S. aureus isolates recovered in culture using immunochromatography. This technique is
dependent upon anti-PBP2a monoclonal antibodies applied to a nitrocellulose membrane (7). If PBP2a
is detected, the isolate is assumed to be methicillin (␤-lactam)-resistant S. aureus. Conversely, if PBP2a is
not detected, the isolate is classiﬁed as methicillin (␤-lactam)-susceptible S. aureus. The PBP2a SA culture
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TABLE 1 PBP2a culture colony test and PBP2a SA culture colony test results
Staphylococcus
species (n)
S. capitis (8)
S. caprae (3)
S. epidermidis (50)
S. haemolyticus (3)
S. hominis (12)
S. lugdunensis (9)
S. pseudintermedius (6)
S. schleiferi (6)
S. simulans (1)
S. warneri (2)
All species (100)

No. of
mecA-negative
isolates
7
2
14
2
8
5
3
3
1
2
47

No. of negative
PBP2a culture
colony tests
7
2
27
3
11
5
3
3
1
2
64

No. of negative
PBP2a SA culture
colony tests
7
2
14
2
8
5
3
3
1
2
47

No. of
mecA-positive
isolates
1
1
36
1
4
4
3
3
0
0
53

No. of positive
PBP2a culture
colony tests
1
1
23
0
1
4
3
3
0
0
36

No. of positive
PBP2a SA culture
colony tests
1
1
36
1
4
4
3
3
0
0
53
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colony test is a revised version of the PBP2a culture colony test that employs recombinant anti-PBP2a
monoclonal antibody fragments bound to a nitrocellulose membrane (10). To determine the accuracy of
both assays compared to that of mecA PCR results, testing was performed according to the manufacturer’s instructions without oxacillin or cefoxitin induction. All testing of the PBP2a culture colony test
was performed at one site (Children’s Healthcare of Atlanta), while testing of the PBP2a SA culture colony
test was performed at another site (NewYork-Presbyterian Hospital–Weill Cornell Medical Center). The
testing was performed by a single operator. It was not possible to test the collection of isolates
simultaneously with both versions of the assay. To ensure consistency with the timing of testing, all
isolates were tested with each test version after 22 to 24 h of incubation (which is within the 18- to 24-h
time frame in which testing is typically performed) on tryptic soy agar with 5% sheep blood at 35°C in
5 to 10% carbon dioxide. On each day of testing, positive (S. aureus ATCC 43300) and negative (S. aureus
ATCC 25923) controls were performed. The reproducibility (precision) of the PBP2a SA culture colony test
for non-SASS was determined using two representative isolates of S. epidermidis, one mecA negative and
the other mecA positive, at a single site (NewYork-Presbyterian Hospital–Weill Cornell Medical Center).
Each isolate was tested in triplicate on three different days by three different operators using three
different lot numbers of kits to assess the intra- and interassay reproducibility of the test. On each day
of reproducibility testing, positive (S. aureus ATCC 43300) and negative (S. aureus ATCC 25923) controls
were performed.
Data analysis. A true positive (TP) was deﬁned as a positive immunochromatographic assay in the
setting of a positive mecA PCR. A true negative (TN) was deﬁned as a negative immunochromatographic
assay in the setting of a negative mecA PCR. A false positive (FP) was deﬁned as a positive immunochromatographic assay in the setting of a negative mecA PCR. A false negative (FN) was deﬁned as a
negative immunochromatographic assay in the setting of a positive mecA PCR. Sensitivity and
speciﬁcity were calculated using the following equations: [TP/(TP ⫹ FN)] ⫻ 100 or [TN/(TN ⫹ FP)] ⫻ 100,
respectively. Conﬁdence intervals (CIs) were calculated using MedCalc version 15.1, available at https://
www.medcalc.org (MedCalc Software, Ostend, Belgium). All other data analysis was performed using
Microsoft Excel software.

RESULTS
The mecA status of each isolate was determined using an in-house PCR assay (9),
which identiﬁed 47 mecA-negative and 53 mecA-positive isolates (Table 1). The results
of the mecA PCR were accepted as the gold standard. Cefoxitin and oxacillin disk
diffusion results were concordant with mecA PCR results for 100% of the isolates
tested.
Upon testing the collection of 100 isolates using the PBP2a culture colony test, the
sensitivity and speciﬁcity were determined to be 67.9% (95% CI, 53.7 to 80.1%) and
100% (95% CI, 92.5 to 100%), respectively. Notably, there were 17 false-negative results
when compared to mecA PCR, consisting of 13 S. epidermidis isolates (13/36 mecApositive S. epidermidis isolates; 36.1%), three S. hominis isolates (3/4 mecA-positive S.
hominis isolates; 75%), and one S. haemolyticus isolate (1/1 mecA-positive S. haemolyticus isolate; 100%). The 17 isolates that exhibited false-negative results were from four
of the ﬁve sites, as follows: six from site 1 (6/17 mecA-positive isolates; 35.3%), four from
site 2 (4/11 of mecA-positive isolates; 36.4%), one from site 3 (1/9 mecA-positive isolates;
11.1%), and six from site 5 (6/12 mecA-positive isolates, 50.0%). While the 13 S.
epidermidis false-negative results were for isolates obtained from sites 1, 2, 3, and 5, the
three S. hominis isolates that yielded false-negative results were from site 2 (however,
site 2 was the only site that provided mecA-positive S. hominis isolates; n ⫽ 4), and the
April 2019 Volume 57 Issue 4 e01417-18
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one S. haemolyticus isolate with a false-negative result was from site 1 (which was the
only site to provide a mecA-positive S. haemolyticus isolate). The false-negative results
reported for various species and isolates from multiple centers suggest that these
data more likely reﬂect true assay performance as opposed to a speciﬁc characteristic associated with clonal isolates. In contrast, testing of the collection of 100
isolates using the revised version of the assay, the PBP2a SA culture colony test,
demonstrated 100% sensitivity (95% CI, 93.3 to 100%) and 100% speciﬁcity (95% CI,
92.5 to 100%). Data are summarized in Table 1. Finally, the intra- and interassay
reproducibility of the PBP2a SA culture colony test was 100%.
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DISCUSSION
Our data suggest that the PBP2a SA culture colony test has superior sensitivity for
detecting PBP2a-mediated ␤-lactam resistance in non-SASS compared to that of the
PBP2a culture colony test (100% versus 67.9%, respectively), while both assays have a
speciﬁcity of 100%. These results are consistent with the known improved afﬁnity
of recombinant monoclonal antibody fragments compared to that of monoclonal
antibodies, given the ability for facile antibody engineering and manipulation to
improve performance (17). Recombinant antibody fragments are also advantageous
because the absence of the fragment crystallizable region (Fc) domain reduces
nonspeciﬁc binding, and antigen detection is often enhanced through decreased
steric hindrance (17).
Interestingly, the reduced sensitivity of the PBP2a culture colony test was limited to
three of the 10 species tested, S. epidermidis, S. hominis, and S. haemolyticus. It remains
unclear if this represents a true limitation of this assay for these three species or if an
insufﬁcient number of isolates were tested for the remaining seven species. Our data
demonstrated a reduced sensitivity when using the PBP2a culture colony test for
non-SASS compared to that in a recent report (8). This discrepancy may be due to
differences in the speciﬁc non-SASS isolates included in each study and/or due to a
larger number of isolates evaluated in this current study. Nonetheless, our data show
that the revised version of the assay, the PBP2a SA culture colony test, displays 100%
sensitivity and speciﬁcity across 10 clinically relevant non-SASS. As such, the PBP2a SA
culture colony test offers a rapid, reproducible, and inexpensive test for PBP2a detection in medically and veterinary-relevant Staphylococcus species.
The PBP2a SA culture colony test is only U.S. Food and Drug Administration cleared
for testing S. aureus isolates. However, this assay allows laboratories to readily address
the CLSI recommendation to test isolates of Staphylococcus species (other than S.
aureus, S. lugdunensis, S. epidermidis, S. pseudintermedius, and S. schleiferi) with oxacillin
MIC values between 0.5 and 2 g/ml recovered from serious infections for the presence
of mecA or PBP2a, because some of these strains may lack mecA (and ultimately PBP2a),
and oxacillin MIC breakpoints may overcall resistance (16). In this situation, it is our
recommendation that isolates that test mecA or PBP2a negative should be reported as
oxacillin susceptible.
In conclusion, while molecular testing for mecA remains the gold standard for
detecting mecA-mediated ␤-lactam resistance in staphylococci, PBP2a immunoassays,
such as the PBP2a SA culture colony test, are invaluable tools for the management of
infections due to Staphylococcus species and for antimicrobial stewardship efforts due
to their rapid time to result, low cost, and ease of implementation and use in any
laboratory, including those in austere settings. Through this work, we provide a framework
for validating the PBP2a SA culture colony test for testing non-SASS as a laboratorydeveloped test, which should be of practical use to clinical laboratories.
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